Drug intelligence / Profile preview

hydrocortisone + infliximab

Development stage: Unknown
Lead developer: AbbVie
Modality: Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
Administration: Intravenous

Overview

A combination therapy consisting of hydrocortisone, a glucocorticoid with anti-inflammatory properties, and infliximab, a monoclonal antibody targeting tumor necrosis factor-alpha (TNF-α). This combination is primarily used in the treatment of inflammatory bowel disease (IBD), with hydrocortisone often serving as a premedication for infliximab infusions to reduce the risk of antibody formation and infusion-related reactions. The combination has synergistic immunosuppressive effects but may increase the risk of opportunistic infections.

Targets

GR (Glucocorticoid receptor)TNFA (Tumor necrosis factor alpha (soluble))MR (Mineralocorticoid receptor)

Beyond the preview

Go deeper on hydrocortisone + infliximab.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on hydrocortisone + infliximab.

Explore the full profile